KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Other Non-Current Liabilities (2016 - 2022)

Inovio Pharmaceuticals (INO) has disclosed Other Non-Current Liabilities for 13 consecutive years, with $710348.0 as the latest value for Q3 2022.

  • Quarterly Other Non-Current Liabilities rose 1007.48% to $710348.0 in Q3 2022 from the year-ago period, while the trailing twelve-month figure was $710348.0 through Sep 2022, up 1007.48% year-over-year, with the annual reading at $14826.0 for FY2021, 74.29% down from the prior year.
  • Other Non-Current Liabilities hit $710348.0 in Q3 2022 for Inovio Pharmaceuticals, up from $14826.0 in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $119.8 million in Q2 2020 to a low of $14826.0 in Q4 2021.
  • Historically, Other Non-Current Liabilities has averaged $8.7 million across 5 years, with a median of $64141.0 in 2021.
  • Biggest five-year swings in Other Non-Current Liabilities: skyrocketed 235895.43% in 2020 and later crashed 99.95% in 2021.
  • Year by year, Other Non-Current Liabilities stood at $228665.0 in 2018, then surged by 3756.74% to $8.8 million in 2019, then crashed by 99.35% to $57663.0 in 2020, then tumbled by 74.29% to $14826.0 in 2021, then skyrocketed by 4691.23% to $710348.0 in 2022.
  • Business Quant data shows Other Non-Current Liabilities for INO at $710348.0 in Q3 2022, $14826.0 in Q4 2021, and $64141.0 in Q3 2021.